MAPK: A promising signaling pathway in targeted therapy for the treatment of NSCLC

Aberrant stimulation of MAPK (Mitogen-activated protein kinase) signaling pathway triggers the dysregulated cell growth and resistance to apoptosis in a wide variety of tumors especially in NSCLC (Nonsmall cell lung cancer). Most of the research is on treating lung cancer by targeting the MAPK pathway receptors. Nevertheless, it is essential to consider interconnections and mode of action to resolve the drug resistance ad feedback loops during the treatment with checkpoint inhibitors. Here we describe the overall mechanism of MAPK pathway, oncogenic mutations and precise information regarding the drug compounds for each receptor in this pathway. Further, in-depth insights into this review could be beneficial for the empathetic discovery of inhibitors for NSCLC against this pathway.